Clinical Trial Search

Primary: Postprandial Pulse Wave Velocity (PWV) in Type 2 Diabetes Mellitus (T2DM) Participants at 30 Minutes (Mins) Pre-Breakfast — 10.99; 10.73; 11.56; 11.31 meters per second…

Primary: Mean Area Under the Curve for Rise in Breakfast Post-prandial. — 61; 583 min x (mmol/l)

Primary: Monocyte NfkB Levels as Detected by Western Blotting — 62.79; 72.03; 67.68; 84.19 NfkB p65 arbitrary units

Primary: Mean Plasma Glucose Area Under the Curve (AUC 0-3h) — 22,192.5; 25,207.1; 21,715.9 mg*min/dl

Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001

Primary: Measurement of the Area Under the Curve of Plasma Triglycerides (TG) Levels During Postprandial Period (Time 0,2,4,6,8 Hours) — 30.0; 27.1 mmol*h/L

Primary: Number of Participants Who Experienced a Primary Combined Outcome — 174; 181 participants — p=0.866

Primary: Change in Area Under the Concentration-time Curve (AUC1-4h) for Postprandial Plasma Glucose From Baseline After 28 Days of Treatment — -18.07; -103.56; -122.94 mg*h/dL…

Primary: Glucose Nadir After Mizagliflozin Dosing — 6.2; 4.0; 17.5; 31.5 mg/dL

Primary: The Difference Between Pre- and 120 Minute Post-prandial Blood Glucose Concentrations at Lunch. — 146.69; 143.68; 149.02 mg/dl — p=.971

Primary: Change From Baseline in Postprandial Glucose Excursion (PPGE) at the End of the Study (Week 4) — -1.775; -2.434 mmol/L

Primary: Hepatic Fat Fraction — 8.35 Percent

Primary: Plasma Glucose Level Post-meal (AUC [0-4]) — 28426; 33911 min*pg/ml

Primary: Postprandial Glycaemia — 11.3; 15.2; 17.8; 27.1 mmol/L*min

Primary: Glycemic Index — 76.79; 86.92 percentage of AUC from GI100 — p=0.005

Primary: Fasting Plasma Glucose — 77.4; 77.7 mmol/L

Primary: Disposition Index — 708; 793; 791 unitless

Primary: Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours — 301.09; 258.66; 248.63; 274.13 mmol x min/L — p=0.1146

Primary: Lowering of Fasting Glucose — 5.78; 5.83 mmol/l — p=>0.05

Primary: The Area Under the Curve (AUC) of Plasma Glucose (PG) Concentrations During the 5-hour Postprandial Period (AUC-PG0-5 h). — 724.6; 668.8 mg*h/dl

Primary: Change in Endogenous Glucose Production — 1.47; 1.46; 1.44; 1.37 mg/kg/min

Primary: Hospital Length of Stay — 7; 8 days

Primary: Area Under the Curve (AUC) of Plasma Total GLP-1 Levels After Intake of the Study Meal — 10.5; 10.5 pM x hr/L

Primary: Measurement of the Change in Plasma Glucose (mg/dL): Study 1 — -29; -17 mg/dl

Primary: Post-prandial Blood Glucose Concentration in Both Pramlintide and Exenatide Treated Groups in Acute and Chronic Setting, Compared to Insulin Monotherapy in Type 1…

Primary: Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo — -5.2; -9.4; -8.8 umol/L — p=0.57

Primary: Change From Baseline in Fasting Plasma Glucose at Day 1 — 0.20; 0.39; -0.96; -0.47 mmol/L — p=0.2790

Primary: Change in HbA1c From Baseline — 0.015; 0.030 % (HbA1c) — p=0.933

Primary: Change in Flow Mediated Dilation (FMD) Between Baseline and After 2 Hour Insulin Clamp — 11.8; 11.8; 8.9; 8.95 % change

Primary: Glucagon-like Peptide-1 Secretion After Meal Ingestion — 0.82; 1.24 nmol/l/min